Novel Biological Agents for the Treatment of Hormone-Refractory Prostate Cancer (HRPC)

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|12|3|277-296

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.12, Iss.3, 2005-02, pp. : 277-296

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 6, 2013-05 ,pp. : 915-920

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment Options in Hormone-Refractory Prostate Cancer: Current and Future Approaches

By Harris K.A.   Reese D.M.  

Drugs, Vol. 61, Iss. 15, 2001-01 ,pp. : 2177-2192

Adis International

Access to resources Recommend Favorite

Which drug combination for hormone-refractory prostate cancer?

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 667-670

Informa Healthcare

Access to resources Recommend Favorite

Docetaxel: In Hormone-Refractory Metastatic Prostate Cancer

By McKeage Kate   Keam Susan J.  

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2287-2294

Adis International

Access to resources Recommend Favorite

Docetaxel in Hormone-Refractory Metastatic Prostate Cancer: A Viewpoint by William R. Berry

By Berry William R.  

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2295-2297

Adis International

Access to resources Recommend Favorite